Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

21.72
+0.77003.68%
Post-market: 21.71-0.0100-0.05%19:44 EDT
Volume:1.62M
Turnover:34.84M
Market Cap:2.18B
PE:-4.70
High:21.95
Open:21.00
Low:20.55
Close:20.95
Loading ...

Beam Therapeutics Shares up 10.4% Premarket After Early-Stage Data for Gene Editing Therapy

THOMSON REUTERS
·
10 Mar

BRIEF-Beam Therapeutics Announces Pricing Of Underwritten Offering

Reuters
·
10 Mar

BRIEF-Beam Therapeutics BEAM-302 Was Well Tolerated At All Dose Levels

Reuters
·
10 Mar

Beam Therapeutics: Single Dose of Beam-302 Led to Durable, Dose-Dependent Increases in Total and Functional Alpha-1 Antitrypsin

THOMSON REUTERS
·
10 Mar

Beam Therapeutics: Pricing of Underwritten Offering of 16.2 Mln Shares at Price $28.48 per Share

THOMSON REUTERS
·
10 Mar

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

GlobeNewswire
·
10 Mar

AI Biotech Stocks Shined, With Ginkgo Up 8%, Recursion And Absci Up 4%, Crispr Up 3%

Tiger Newspress
·
05 Mar

Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%

Benzinga
·
05 Mar

Beam Therapeutics Inc : Scotiabank Raises Target Price to $25 From $24

THOMSON REUTERS
·
03 Mar

Cautious Optimism for Beam Therapeutics Amid Upcoming Milestones and Financial Considerations

TIPRANKS
·
28 Feb

Beam Therapeutics Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
27 Feb

Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates

Zacks
·
26 Feb

Beam Therapeutics: Anticipated Growth Driven by BEAM-302 and SCD Franchise Progress

TIPRANKS
·
26 Feb

RBC Raises Price Target on Beam Therapeutics to $26 From $24, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
26 Feb

Bank of America Securities Keeps Their Hold Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
26 Feb

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS) and Beam Therapeutics (BEAM)

TIPRANKS
·
26 Feb

Beam Therapeutics (BEAM) Gets a Hold from Barclays

TIPRANKS
·
26 Feb

Beam Therapeutics Inc : Jefferies Raises Target Price to $30 From $23

THOMSON REUTERS
·
26 Feb

Beam Therapeutics Reports 2024 Financial Results and Progress

TIPRANKS
·
26 Feb

Beam Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Feb